Dividends can be a great way to generate income from stocks, no matter what the market is doing. But only if the companies ...

RBC Capital analyst Nik Modi maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $24.00. The ...

Merely weeks into Andrew Stanleick's tenure at Kenvue, his vision for Neutrogena is coming into focus. Shortly after naming ...

Kenvue (NYSE:KVUE – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on ...

Kenvue Inc. closed 12.96% below its 52-week high of $24.46, which the company reached on November 26th.

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

LISTERINE®, a flagship oral care brand under Kenvue, announced its upcoming participation in AEEDC 2025, the world's largest dental health ...

Kenvue Inc. (KVUE), a global consumer health company, is dedicated to delivering trusted personal care, health, and wellness products. Headquartered in Skillman, New Jersey, Kenvue offers a ...

Kenvue Inc . (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson in 2023, finds itself at a critical juncture as it navigates its first full year as an independent entity.

Barclays analyst Lauren Lieberman maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $21.00. The ...

L’Oréal veteran Penelope Giraud will lead the direction of the company’s beauty brands Neutrogena, Aveeno and Dr. Ci Labo in ...